RBC Capital analyst Lisa Walter raised the firm’s price target on United Therapeutics (UTHR) to $587 from $569 and keeps an Outperform rating on the shares. The company’s Q3 results support the firm’s view that Tyvaso will continue to grow irrespective of new market entrants, IPF could double the top-line to over $6B in the next 5 years, and the base business will show resiliency, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results
- United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation
- Strong Growth Potential and Strategic Initiatives Drive Buy Rating for United Therapeutics